Download PDF
Thromb Haemost 2000; 83(06): 902-905
DOI: 10.1055/s-0037-1613941
Commentary
Schattauer GmbH

Plasma TAFI Antigen Variations in Healthy Subjects

P. Chetaille
2   From the Laboratory of Hematology, University of Medicine La Timone, Marseille, France
,
M. C. Alessi
2   From the Laboratory of Hematology, University of Medicine La Timone, Marseille, France
,
D. Kouassi
1   Faculty of Pharmacy, Abidjan, Ivory Coast
,
P. E. Morange
2   From the Laboratory of Hematology, University of Medicine La Timone, Marseille, France
,
I. Juhan-Vague
2   From the Laboratory of Hematology, University of Medicine La Timone, Marseille, France
› Author Affiliations
Further Information

Publication History

Received 22 July 1999

Accepted after resubmission 31 January 2000

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

The Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a recently described inhibitor of fibrinolysis. The physiological variations of plasma TAFI antigen are not well known. We studied TAFI antigen values in healthy populations with a commercially available kit from Milan Analytica (Switzerland). Broad range of TAFI antigen values (from 41% to 259%) was found in a population of 249 healthy individuals. Gender as well as pregnancy did not influence mean values of TAFI antigen. There was a positive correlation between TAFI antigen and age in female (r = 0.28; p <0.05) but not in male populations. Mean TAFI antigen value of a black African male group [mean ± SD (range): 87 ± 23 (39-144%)] was significantly lower than the one of age matched Caucasian men [114 ± 34 (52-259%)] (p <0.0001). TAFI antigen values were very stable within individuals, they did not significantly vary on day time or at several months period.

Thus, in contrast to large inter-individual variations, TAFI antigen levels are quite stable within individuals.

Keywords

TAFI - carboxypeptidase B - physiological variations - healthy population
 

  • References

  • 1 Hendricks D, Scharpé S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
    PubMedGoogle Scholar
  • 2 Campbell W, Okada H. An arginin specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
    CrossrefPubMedGoogle Scholar
  • 3 Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
    PubMedGoogle Scholar
  • 4 Bajzar L, Manuel R, Neisheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14777-84.
    PubMedGoogle Scholar
  • 5 Bajzar L, Morser J, Neisheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
    CrossrefPubMedGoogle Scholar
  • 6 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14777-88.
    PubMedGoogle Scholar
  • 7 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
    CrossrefPubMedGoogle Scholar
  • 8 Bajzar L, Neisheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
    PubMedGoogle Scholar
  • 9 Wang M, Nagashima M, Morser J. Thrombin activable fibrinolysis inhibitor in rats, rabbits and dogs. Fibrinolysis & Proteolysis 1998; 12 (Suppl. 01) 12.
    PubMedGoogle Scholar
  • 10 Von dem Borne PAK, Bajzar L, Meijers JCM, Neisheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a Thrombin-Activatable Fibrinolysis Inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
    CrossrefPubMedGoogle Scholar
  • 11 Broze Jr G, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
    PubMedGoogle Scholar
  • 12 Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-52.
    CrossrefPubMedGoogle Scholar
  • 13 Hudson I, De Bono DP. Levels of carboxypeptidase B (thrombin-activable fibrinolysis inhibitor: TAFIa) following thrombolysis with streptokinase. Fibrinolysis & Proteolysis 1998; 12 (Suppl. 01) 12.
    PubMedGoogle Scholar
  • 14 Refino CJ, Schmitt D, Pater C, Eaton D, Bunting S. A carboxypeptidase inhibitor markedly improves the potency of tPA in vivo. Blood 1998; 92: 550a.
    PubMedGoogle Scholar
  • 15 Neisheim ME. TAFI. Fibrinolysis and Proteolysis 1999; 13: 72-7.
    CrossrefPubMedGoogle Scholar
  • 16 Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
    CrossrefPubMedGoogle Scholar
  • 17 Mosnier LO, von der Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Juhan-Vague I, Alessi MC, Raccah D, Aillaud MF, Billerey M, Ansaldi J, Philip-Joet C, Vague P. Daytime fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost 1992; 67: 76-82.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Schatteman KA, Goossens FJ, Scharpé SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-13.
    PubMedGoogle Scholar